FindTrial
Sign In

Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitis

Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222244
Enrollment
Unknown
Registered
2013-10-03
Start date
2013-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

investigational material(s) Generic name etc : AJM300 INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investiga

Sponsors

Ajinomoto Pharmaceuticals Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with active-phase ulcerative colitis - The Mayo score of 6 to 10. - Mucosal appearance subscore of 2 or more, and Rectal bleeding subscore of 1 or more - Inadequate response to or intolerance of appropriate conventional therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mayo score, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026